NASDAQ:APVO | Free Cash Flow | Aptevo Therapeutics Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2015-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$7.97M
2025-12-31-$5.24M
2025-03-31-$6.58M
2024-12-31-$5.76M
2024-03-31-$6.65M
2023-12-31-$5.25M
2023-03-31$4.57M
2022-12-31-$5.94M$0.00-$5.94M
2022-03-31-$5.12M
2021-12-31-$3.88M$118,000.00-$4M
2021-03-31-$7.5M$191,000.00-$7.7M
2020-12-31-$6.12M
2020-03-31-$11.18M
2019-12-31-$5.1M$0.00-$5.1M
2019-03-31-$13.84M$153,000.00-$14M
2018-12-31-$7.29M$49,000.00-$7.34M
2018-03-31-$16.98M$473,000.00-$17.45M
2017-12-31-$15.42M$297,000.00-$15.72M
2017-03-31-$12.03M$794,000.00-$12.82M
2016-12-31-$6.67M$579,000.00-$7.24M
2016-03-31-$14.11M$1.07M-$15.18M
2015-12-31-$7.68M$515,000.00-$8.2M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$25.59M
2024-12-31-$23.79M
2023-12-31-$11.73M
2022-12-31-$21.02M$29,000.00-$21.05M-262.25%
2021-12-31-$21.68M$713,000.00-$22.39M
2020-12-31-$29.32M$88,000.00-$29.41M
2019-12-31-$42.38M$153,000.00-$42.54M
2018-12-31-$51.42M$976,000.00-$52.4M
2017-12-31-$41.57M$1.4M-$42.98M-616.31%
2016-12-31-$36.86M$2.51M-$39.37M
2015-12-31-$48.76M$1.53M-$50.29M